HC Wainwright Analysts Boost Earnings Estimates for Evolus

Evolus, Inc. (NASDAQ:EOLSFree Report) – Stock analysts at HC Wainwright upped their Q4 2024 earnings per share (EPS) estimates for Evolus in a report issued on Wednesday, January 22nd. HC Wainwright analyst D. Tsao now expects that the company will earn $0.00 per share for the quarter, up from their previous forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evolus’ Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.87 EPS, FY2027 earnings at $1.63 EPS and FY2028 earnings at $2.89 EPS.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Tuesday, January 21st.

View Our Latest Stock Analysis on Evolus

Evolus Trading Up 1.5 %

EOLS opened at $14.23 on Friday. The firm’s 50 day moving average is $11.79 and its 200-day moving average is $13.79. Evolus has a 52-week low of $9.25 and a 52-week high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $901.06 million, a P/E ratio of -15.64 and a beta of 1.32.

Institutional Investors Weigh In On Evolus

Several hedge funds and other institutional investors have recently bought and sold shares of EOLS. KBC Group NV acquired a new stake in shares of Evolus during the fourth quarter worth approximately $49,000. Quarry LP acquired a new position in Evolus during the 2nd quarter worth $54,000. Profund Advisors LLC bought a new stake in shares of Evolus in the 2nd quarter worth about $130,000. Point72 Asset Management L.P. bought a new position in shares of Evolus during the third quarter worth about $132,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after purchasing an additional 1,291 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Company Profile

(Get Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Recommended Stories

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.